Autoanti-D in a patient after cladribine treatment for lymphoplasmocytic lymphoma

1Vengelen-Tyler V, ed. Technical manual. 13th ed. Bethesda, MD: American Association of Blood Banks, 1999.Search in Google Scholar

2Saba NF, Sweeney JD, Lawton JC, Yankee RL, Huang CH, Schanfield MS. Anti-D in a D-positive renal transplant patient. Transfusion 1997;37:321-4.10.1046/j.1537-2995.1997.37397240216.x9122907Search in Google Scholar

3Mollison PL, Engelfriet CP, Contreras M. Blood transfusion in clinical medicine. 10th ed. Oxford: Blackwell Science, 1997.Search in Google Scholar

4Rozman C, Montserrat E. Chronic lymphocytic leukemia. N Engl J Med 1995;333:1052-7.10.1056/NEJM1995101933316067675049Search in Google Scholar

5Bergman L. Present status of purine analogs in the therapy of chronic lymphocytic leukemias. Leukemia 1997;11(Suppl 2):S29-S34.Search in Google Scholar

6Dimopoulos MA, Panayiotidis P, Moulopoulos LA, Sfikakis P, Dalakas M. Waldenström’s macroglobulinemia: clinical features, complications and management. J Clin Oncol 2000;18:214-26.10.1200/JCO.2000.18.1.21410623712Search in Google Scholar

7Tetreault SA, Saven A. Delayed onset of autoimmune hemolytic anemia complicating cladribine therapy for Waldenström’s macroglobulinemia. Leukemia and Lymphoma 2000;37:125-30.10.3109/1042819000905763510721776Search in Google Scholar

8Gassner C, Schmarda A, Kilga-Nogler S, et. al. Rhesus D/CE typing by polymerase chain reaction using sequence-specific primers. Transfusion 1997; 37:1020-26.10.1046/j.1537-2995.1997.371098016439.x9354819Search in Google Scholar

9Callaghan TA, Fleetwood P, Contreras M, Scherrmann JM. Human monoclonal anti-D with a normal halflife. Transfusion 1993;33:784-5.10.1046/j.1537-2995.1993.33994025031.x8212126Search in Google Scholar

10Petz LD, Garratty G. Mechanisms of immune hemolysis. In: Petz LD, Garratty G, eds. Acquired immune hemolytic anemias. London: Churchill Livingston, 1980:110-38.Search in Google Scholar

11Issitt PD. Serology and genetics of the Rhesus blood group system. Cincinnati, OH: Montgomery Scientific Publications 1979:161-7.Search in Google Scholar

12Avent ND, Reid ME. The Rh blood group system: a review. Blood 2000;95:375-87.10.1182/blood.V95.2.375Search in Google Scholar

13Vagace JM, Bureo JC, Groiss J, et al. Autoanticuerpos con especificidad anti-D. Comunicación de dos casos y revisión del tema. Haematologica 2000;85:375-87.Search in Google Scholar

14Myint H, Copplestone JA, Orchand J, et. al. Fludarabine-related autoimmune hemolytic anemia in patients with chronic lymphocytic leukemia. Br J Haematol 1995;91:341-4.10.1111/j.1365-2141.1995.tb05300.x8547072Search in Google Scholar

15Juliusson G. Complications in the treatment of CLL with purine analogues. Haematology Cell Ther 1997;39:S41-S44.10.1007/PL00021052Search in Google Scholar

16DiRaimondo F, Giustolisi R, Cacciola E, et al. Autoimmune hemolytic anemia in chronic lymphocytic leukemia patients treated with fludarabine. Leukemia Lymphoma 1993;11:63-8.10.3109/104281993090547318220155Search in Google Scholar

17Robak T, Blasinska-Morawiec M, Kryowski E, Hellman A, Konopa L. Autoimmune hemolytic anemia in patients with chronic lymphocytic leukemia treated with 2-chlorodeoxyadenosine (cladribine). Eur J Haematol 1997;58:109-13.10.1111/j.1600-0609.1997.tb00933.x9111592Search in Google Scholar

18Cheson BD. Infections and immunosuppressive complications of purine analog therapy. J Clin Oncol 1995;13:28-33.10.1200/JCO.1995.13.9.2431Search in Google Scholar

19Kong LR, Huang C, Hakimian D, et al. Long term follow-up and late complications of 2-chlorodeoxyadenosine in previously treated, advanced, indolent non-Hodgkin’s lymphoma. Cancer 1998;82:957-64.10.1002/(SICI)1097-0142(19980301)82:5<957::AID-CNCR22>3.0.CO;2-ZSearch in Google Scholar

20Fleischman A, Croy D. Acute onset of severe autoimmune hemolytic anemia after treatment with 2-chlorodeoxyadenosine for chronic lymphocytic leukemia (letter). Am J Haematol 1995;48:293.10.1002/ajh.2830480423Search in Google Scholar

21Piro LD, Carrera CJ, Beutler E, Carson DA. 2-chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia. Blood 1988;72:1069-73.10.1182/blood.V72.3.1069.bloodjournal7231069Search in Google Scholar

22Weiss RB, Freeman J, Kweder SL, Diehl LF, Byrd JC. Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia. J Clin Oncol 1998;16:1885-9.10.1200/JCO.1998.16.5.1885Search in Google Scholar

23Byrd JC, Hertler AA, Weiss RB, Freimann J, Kweder SL, Dieth LF. Fatal recurrence of autoimmune hemolytic anemia following pentostatin therapy with a history of fludarabine-associated hemolytic anemia. Ann Oncol 1995;6:300-1.10.1093/oxfordjournals.annonc.a059162Search in Google Scholar